TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Regeneron Pharmaceuticals, Inc.
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Regeneron announced positive Phase 2 trial results for two novel factor XI antibodies (REGN7508Cat and REGN9933A2) that demonstrate robust anti-clotting effects with minimal bleeding risk in patients undergoing total knee replacement surgery.

Insights
GSpC   neutral

Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement


REGN   positive

Successfully demonstrated promising Phase 2 trial results for novel antibodies with potential to improve anticoagulation therapy, showing reduced venous thromboembolism rates and minimal bleeding risks